Clinical development failure
TCR-T candidates may not demonstrate sufficient safety or efficacy in trials.
- Scope
- Lead programs TSC-101 and TSC-102 series
- Materiality
- high
TScan Therapeutics, Inc.
TScan Therapeutics is a U.S.-based clinical-stage biotechnology company developing T cell receptor-engineered T cell, or TCR-T, therapies for cancer. Its platform centers on an ImmunoBank of therapeutic TCRs and a pipeline of product candidates for hematologic malignancies and solid tumors, with research, manufacturing, and development activities based in the United States.
−1 287,3 %
−1 256,8 %
+266,7 %
8.41
8.41
| % | |
|---|---|
| Clinical-stage TCR-T therapies | 0% Engineered T cell therapies designed to recognize cancer targets through specific T cell receptors. |
| ImmunoBank platform | 0% A proprietary repository of therapeutic TCRs used to build and expand the pipeline. |
| Research collaborations and licenses | 100% Partnered discovery and licensing arrangements that generate collaboration revenue. |
TScan’s direct customers are primarily pharmaceutical and biotechnology partners that license or collaborate on TCR...
- Pharmaceutical collaboration partnersprimary
Companies such as Amgen that fund research, receive data, and retain commercialization rights in partnered programs.
- Biotechnology research partnerssecondary
Smaller or specialized biotech firms that may license TCR discovery capabilities or collaborate on antigen identification.
- Cancer patientsprimary
Patients with hematologic or solid tumor cancers who would receive TCR-T therapies in clinical trials or after approval.
- Hospitals and oncology treatment centerssecondary
Clinical sites that enroll patients, administer cell therapy products, and support trial logistics.
TScan is headquartered and operates primarily in the United States, where its corporate, research, and manufacturing...
- •Headquartered in the United States
- •Manufacturing facility in Waltham, Massachusetts
- •Clinical development and research are U.S.-based
- •Current revenue is from U.S.-based collaboration activity
- •Future commercialization could expand internationally
TScan’s strategy is to build a differentiated TCR-T pipeline using its ImmunoBank platform and to advance lead programs...
01
Advance TSC-101 and next heme programsshort-term
Clinical proof-of-concept is needed to validate the platform and support later-stage development.
02
Expand the ImmunoBank platformmedium-term
A broader TCR library increases the number of target/HLA combinations the company can pursue.
03
Strengthen manufacturing and process readinessmedium-term
Cell therapy development depends on reproducible, scalable, and controlled manufacturing.
TScan faces the typical risks of a clinical-stage cell therapy company: uncertain clinical outcomes, regulatory review...
Regulatory and safety scrutiny
The FDA may require additional monitoring, labeling, or trial changes for engineered T-cell products.
- Scope
- All TCR-T product candidates
- Materiality
- high
Financing dependence
The company has no approved therapies and must fund development through external capital and collaborations.
- Scope
- Corporate liquidity and pipeline execution
- Materiality
- high
Competitive pressure
Multiple companies are developing TCR-based and other cell therapies for similar cancer indications.
- Scope
- TCR space and broader cell therapy market
- Materiality
- high
Manufacturing complexity
Cell therapies require controlled, reproducible manufacturing and supply chain reliability.
- Scope
- Clinical supply and future scale-up
- Materiality
- medium
Collaboration revenue recognition
Affects reported revenue timing and comparability across quarters
Research and development accruals
Can shift operating expense recognition between periods
Stock-based compensation
Affects operating loss and diluted share calculations
Debt issuance and financing costs
Influences interest expense and balance sheet presentation
TG THERAPEUTICS, INC.
TGTX · Pharmaceutical Preparations
TG Therapeutics is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases and related immune-mediated disorders.
INSMED Inc
INSM · Pharmaceutical Preparations
INSMED Inc is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for serious respiratory and other high-unmet-need diseases.
Tvardi Therapeutics, Inc.
TVRD · Pharmaceutical Preparations
Tvardi Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for fibrosis-driven diseases and certain cancers.
Rein Therapeutics, Inc.
RNTX · Pharmaceutical Preparations
MANNKIND CORP
MNKD · Pharmaceutical Preparations
MannKind Corp is a biopharmaceutical company focused on developing and commercializing inhaled and other specialty therapies, with a commercial base in diabetes and cardiopulmonary care.
Stoke Therapeutics, Inc.
STOK · Pharmaceutical Preparations
: 29.4.2026